XNAS · Healthcare · Biotechnology
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | Q1 2026 | -0.15 | -0.15 | +0.00% | $2.4M | ➖ Inline | +0.00% | -10.63% | -10.00% |
| 2026-03-12 | Q4 2025 | -0.08 | -0.09 | -12.50% | $5.5M | ❌ Miss | +1.66% | -7.56% | +7.56% |
| 2025-11-06 |
| Q3 2025 |
| -0.10 |
| -0.10 |
| +0.00% |
| $2.9M |
| ➖ Inline |
| — |
| — |
| — |
| 2025-03-13 | Q4 2024 | -0.15 | -0.10 | +33.33% | $4.6M | ✅ Beat | -2.87% | -6.32% | -32.18% |
| 2024-11-07 | Q3 2024 | -0.11 | -0.11 | +0.00% | $4.2M | ➖ Inline | +5.60% | +10.64% | -3.36% |
| 2024-03-13 | Q4 2023 | — | -0.08 | — | $3.5M | — | — | — | — |
| 2023-11-07 | Q3 2023 | -0.09 | -0.08 | +11.11% | $1.5M | ✅ Beat | +0.00% | +8.89% | +51.11% |
| 2023-05-16 | Q1 2023 | -0.12 | -0.12 | +1.67% | $702,973 | ✅ Beat | -1.69% | +4.49% | -4.49% |
Showing last 8 quarters.